This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain substituted amino-azepines, according to Formula I
or pharmaceutically acceptable salts, hydrates, or solvates thereof, wherein:
R
1
is aryl optionally substituted with CN, NO
2
, halogen or H;
R
2
is H, C
1
-C
6
alkyl, C
3
-C
7
cycloalkyl, or C
3
-C
7
heterocycloalkyl;
R
3
is H, OH, O—C
1
-C
6
alkyl, SH, S—C
1
-C
6
alkyl, or F;
R
4
is H, C
1
-C
6
alkyl
R
5
is iso-butyl, cyclohexylmethyl, or cyclopentylmethyl; and
R
6
is aryl, heteroaryl.